~~<i id='909DBF2131'><strike id='909DBF2131'><tt id='909DBF2131'><pre id='909DBF2131'></pre></tt></strike></i>~~

Home» focus» focus

focus

author：entertainment 2025-09-30 15:26:15 Page View：917

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Judge agrees to delay next hearing in Trump classified documents case
Next article： The high cost of giving birth even with insurance

comprehensive

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

STAT series 'Denied by AI' wins major journalism prizes

MikeReddyforSTATDearReaders,PleasebearwithmeasIbragabouttwoofSTAT’smostaccomplished(andhumble)report

Hepatitis C has a cure — but many Americans still lack access to it

AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

Ripples from Flovent's discontinuation is killing children with asthma

GettyImagesAspediatricianswhotakecareofchildrenintheinpatient,emergency,andprimarycaresettings,weare

WSS

focus

focus

Wikipedia

comprehensive

Ripples from Flovent's discontinuation is killing children with asthma